215 related articles for article (PubMed ID: 23833311)
1. PARP-1 regulates resistance of pancreatic cancer to TRAIL therapy.
Yuan K; Sun Y; Zhou T; McDonald J; Chen Y
Clin Cancer Res; 2013 Sep; 19(17):4750-9. PubMed ID: 23833311
[TBL] [Abstract][Full Text] [Related]
2. Cytoplasmic PARP-1 promotes pancreatic cancer tumorigenesis and resistance.
Xu F; Sun Y; Yang SZ; Zhou T; Jhala N; McDonald J; Chen Y
Int J Cancer; 2019 Jul; 145(2):474-483. PubMed ID: 30614530
[TBL] [Abstract][Full Text] [Related]
3. Calmodulin antagonists promote TRA-8 therapy of resistant pancreatic cancer.
Yuan K; Yong S; Xu F; Zhou T; McDonald JM; Chen Y
Oncotarget; 2015 Sep; 6(28):25308-19. PubMed ID: 26320171
[TBL] [Abstract][Full Text] [Related]
4. PARP inhibition restores extrinsic apoptotic sensitivity in glioblastoma.
Karpel-Massler G; Pareja F; Aimé P; Shu C; Chau L; Westhoff MA; Halatsch ME; Crary JF; Canoll P; Siegelin MD
PLoS One; 2014; 9(12):e114583. PubMed ID: 25531448
[TBL] [Abstract][Full Text] [Related]
5. Poly(ADP-ribose) polymerase inhibitors sensitize cancer cells to death receptor-mediated apoptosis by enhancing death receptor expression.
Meng XW; Koh BD; Zhang JS; Flatten KS; Schneider PA; Billadeau DD; Hess AD; Smith BD; Karp JE; Kaufmann SH
J Biol Chem; 2014 Jul; 289(30):20543-58. PubMed ID: 24895135
[TBL] [Abstract][Full Text] [Related]
6. Regulation of pancreatic cancer TRAIL resistance by protein O-GlcNAcylation.
Yang SZ; Xu F; Yuan K; Sun Y; Zhou T; Zhao X; McDonald JM; Chen Y
Lab Invest; 2020 May; 100(5):777-785. PubMed ID: 31896813
[TBL] [Abstract][Full Text] [Related]
7. Combination treatment with TRA-8 anti death receptor 5 antibody and CPT-11 induces tumor regression in an orthotopic model of pancreatic cancer.
DeRosier LC; Buchsbaum DJ; Oliver PG; Huang ZQ; Sellers JC; Grizzle WE; Wang W; Zhou T; Zinn KR; Long JW; Vickers SM
Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5535s-5543s. PubMed ID: 17875786
[TBL] [Abstract][Full Text] [Related]
8. Calmodulin antagonist enhances DR5-mediated apoptotic signaling in TRA-8 resistant triple negative breast cancer cells.
Fancy RM; Kim H; Napier T; Buchsbaum DJ; Zinn KR; Song Y
J Cell Biochem; 2018 Jul; 119(7):6216-6230. PubMed ID: 29663486
[TBL] [Abstract][Full Text] [Related]
9. The long non-coding RNA HOTAIR enhances pancreatic cancer resistance to TNF-related apoptosis-inducing ligand.
Yang SZ; Xu F; Zhou T; Zhao X; McDonald JM; Chen Y
J Biol Chem; 2017 Jun; 292(25):10390-10397. PubMed ID: 28476883
[TBL] [Abstract][Full Text] [Related]
10. Treatment of human colon cancer xenografts with TRA-8 anti-death receptor 5 antibody alone or in combination with CPT-11.
Oliver PG; LoBuglio AF; Zinn KR; Kim H; Nan L; Zhou T; Wang W; Buchsbaum DJ
Clin Cancer Res; 2008 Apr; 14(7):2180-9. PubMed ID: 18381960
[TBL] [Abstract][Full Text] [Related]
11. Treatment with gemcitabine and TRA-8 anti-death receptor-5 mAb reduces pancreatic adenocarcinoma cell viability in vitro and growth in vivo.
DeRosier LC; Huang ZQ; Sellers JC; Buchsbaum DJ; Vickers SM
J Gastrointest Surg; 2006 Nov; 10(9):1291-300; discussion 1300. PubMed ID: 17114015
[TBL] [Abstract][Full Text] [Related]
12. Dual combination therapy targeting DR5 and EMMPRIN in pancreatic adenocarcinoma.
Kim H; Zhai G; Samuel SL; Rigell CJ; Umphrey HR; Rana S; Stockard CR; Fineberg NS; Zinn KR
Mol Cancer Ther; 2012 Feb; 11(2):405-15. PubMed ID: 22203731
[TBL] [Abstract][Full Text] [Related]
13. Modulation of TRAIL resistance in colon carcinoma cells: different contributions of DR4 and DR5.
van Geelen CM; Pennarun B; Le PT; de Vries EG; de Jong S
BMC Cancer; 2011 Jan; 11():39. PubMed ID: 21272366
[TBL] [Abstract][Full Text] [Related]
14. The role of K-ras gene mutation in TRAIL-induced apoptosis in pancreatic and lung cancer cell lines.
Sahu RP; Batra S; Kandala PK; Brown TL; Srivastava SK
Cancer Chemother Pharmacol; 2011 Feb; 67(2):481-7. PubMed ID: 20848283
[TBL] [Abstract][Full Text] [Related]
15. Targeted radiotherapy potentiates the cytotoxicity of a novel anti-human DR5 monoclonal antibody and the adenovirus encoding soluble TRAIL in prostate cancer.
Arafat W; Zhou T; Naoum GE; Buchsbaum DJ
J Egypt Natl Canc Inst; 2015 Dec; 27(4):205-15. PubMed ID: 26385392
[TBL] [Abstract][Full Text] [Related]
16. Prediction of proapoptotic anticancer therapeutic response in vivo based on cell death visualization and TRAIL death ligand-receptor interaction.
Zhou L; Wang W; Dicker DT; Humphreys RC; El-Deiry WS
Cancer Biol Ther; 2011 Aug; 12(4):335-48. PubMed ID: 21785270
[TBL] [Abstract][Full Text] [Related]
17. Apoptosis induction in prostate cancer cells and xenografts by combined treatment with Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand and CPT-11.
Ray S; Almasan A
Cancer Res; 2003 Aug; 63(15):4713-23. PubMed ID: 12907654
[TBL] [Abstract][Full Text] [Related]
18. Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAIL.
Hari Y; Harashima N; Tajima Y; Harada M
Oncotarget; 2015 Dec; 6(39):41902-15. PubMed ID: 26506422
[TBL] [Abstract][Full Text] [Related]
19. Galbanic acid potentiates TRAIL induced apoptosis in resistant non-small cell lung cancer cells via inhibition of MDR1 and activation of caspases and DR5.
Kim YH; Shin EA; Jung JH; Park JE; Koo J; Koo JI; Shim BS; Kim SH
Eur J Pharmacol; 2019 Mar; 847():91-96. PubMed ID: 30689998
[TBL] [Abstract][Full Text] [Related]
20. DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.
Yu R; Albarenque SM; Cool RH; Quax WJ; Mohr A; Zwacka RM
Cancer Biol Ther; 2014; 15(12):1658-66. PubMed ID: 25482930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]